Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4- fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors

Journal of Medicinal Chemistry

Volumn 42, Issue 18, 1999, Pages 3647-3656

  Choi, Sung Woon ^a   Elmaleh, David R ^a   Hanson, Robert N ^b   Fischman, Alan J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; N [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL] N' [3 (4 BROMOPHENYL) 2 PROPENYL] 1,2 ETHANEDIAMINE; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DOPAMINE UPTAKE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; LIGAND BINDING; LOCOMOTION; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMIDES; AMINES; ANIMALS; BIOGENIC MONOAMINES; CARRIER PROTEINS; CELL LINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; PIPERAZINES;

EID: 0033539112     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990161h     Document Type: Article

References (37)

1. (a) Johanson, C. E.; Fischman, M. W. The Pharmacology of Cocaine Related to its Abuse. Pharmacol. Rev. 1989, 41, 3-52.
2. (b) Clouet, D.; Asghar, K.; Brown, R.; Eds. Mechanisms of Cocaine Abuse and Toxicity. NIDA Res. Monogr. 1988, 88.
3. Ritz, M. C.; Lamb, R. J.; Goldberg, S. R.; Kuhar, M. J. Cocaine Receptors on Dopamine Transporters are Related to Self-Administration of Cocaine. Science 1987, 237, 1219-1222.
4. Kuhar, M. J.; Ritz, M. C.; Boja, J, W. The Dopamine Hypothesis of the Reinforcing Properties of Cocaine. Trends Neurosci. 1991, 14, 299-302.
5. Carroll, F. I.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine Receptor: Biochemical Characterization and Structure-Activity Relationships of Cocaine Analogs at the Dopamine Transporter. J. Med. Chem. 1992, 35, 969-981.
6. Amara, S. G.; Kuhar, M. J. Neurotransmitter Transporters: Recent Progress. Annu. Rev. Neurosci. 1993, 16, 73-79.
7. Robinson, T. E.; Berridge, K. C. The Neural Basis of Drug Craving: An Incentive-Sensitization Theory of Addicition. Brain Res. Rev. 1993, 18, 247-291.
8. Baumann, M. H.; Char, G. U.; de Costa, B. R.; Rice, K. C.; Rothman, R. B. GBR 12909 Attenuates Cocaine-Induced Activation of Mesolimbic Dopamine Neurons in the Rat. J. Pharmacol. Exp. Ther. 1994, 271, 1216-1222.
9. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and Indifference to Cocaine and Amphetamine in Mice Lacking the Dopamine Transporter. Nature 1996, 379, 606-612.
10. Glowa, J. R.; Wojnicki, F. H.; de Costa, B. R.; Matecka, D.; Rice, K. C.; Rothman, R. B. The Effect of GBR 12909 on Responding of Rhesus Monkeys Maintained under Schedules of Cocaine-and Food-Delivery. NIDA Res. Monogr. 1994, 141, 12.
11. Clarke, R. L.; Daum, S. J.; Gambino, A. J.; Aceto, M. D.; Pearl, J.; Levitt, M.; Cumiskey, W. R.; Bogado, E. F. Compounds Affecting the Central Nervous System. 4. 3β-Phenyl-Tropane-2-Carboxylic Esters and Analogs. J. Med. Chem. 1973, 16, 1260-1267.
12. Van der Zee, P.; Roger, H. S.; Gootjes, J.; Hespe, W. Aryl 1,4-Dialk(en)yl Piperazines as Selective and Very Potent Inhibitors of Dopamine Uptake. Eur. J. Med. Chem. 1980, 15, 363-370.
13. Saadouni, S.; Rafahi-Lyamani, F.; Costentin, J.; Bonnet, J.-J. Cocaine and GBR 12783 recognize nonidentical, overlapping binding domains on the dopamine neuronal carrier. Eur. J. Pharmacol. 1994, 268, 187-197.
14. 3H]-BTCP in rate caudate membranes. J. Pharmacol. Exp. Ther. 1994, 268, 1462-1475.
15. Rothman, R. B.; Mele, A.; Reid, A. A.; Akunne, H,. C.; Greig, N.; Thurkauf, A.; de Costa, B. R.; Rice, K. C.; Pert, A. GBR12909 Antagonizes the Ability of Cocaine to Elevate Extracellular Levels of Dopamine. Pharmacol. Biochem. Behav. 1991, 40, 387-396.
16. Maldonado-irizarry, C. S.; Stellar, J. R.; Kelley, A. E. Effects of cocaine and GBR-12909 on brain stimulation reward. Pharmacol. Biochem. Behav. 1994, 48, 915-920.
17. Tella, S. R.; Ladenheim, B.; Andrews, A. M.; Goldberg, S. R.; Cadet, J. L. Differential Reinforcing Effects of Cocaine and GBR-12909: Biochemical Evidence for Divergent Neuroadaptive Changes in the Mesolimbic Doparminergic System. J. Neurosci. 1996, 16, 7416-7427.
18. 3H]GBR 12935 binding in vitro to rate striatal membranes: Labeling of the dopamine uptake complex. J. Neurochem. 1987, 48, 1887-1896.
19. 3H]GBR 12935 binding in vivo in mouse brain: Labeling of a piperazine acceptor site. Eur. J. Pharmacol. 144, 1-6.
20. Vaughan, R. A. Photoaffinity-Labeled Ligand Binding Domains on Dopamine Transporters Identified by Peptide Mapping. Mol. Pharmacol. 1995, 47, 956-964.
21. Deutsch, H.; Schweri, M. M. Can stimulant binding and dopamine transport be differentiated? Studies with GBR 12783 derivatives. Life Sci. 1994, 55, 115-121.
22. Zhang, Y. The Identification of GBR 12909 as a Potential Therapeutic Agent for Cocaine Abuse. Med. Chem. Res. 1998, 8, 66-76.
23. 3H] DA-uptake-inhibiton to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sci. 1993, 53, 267-272.
24. Matecka, D.; Rice, K. C.; Rothman, R. B.; de Costa, B. R.; Glowa, J. R.; Wojnicki, F. H.; Pert, A.; George, C.; Carroll, F. L; Silverthorn, M. L.; Dersch, C. M.; Becketts, K. M.; Partilla, J. S. Synthesis and absolute configuration of chiral piperazines related to GBR 12909 as dopamine reuptake inhibitors. Med. Chem. Res. 1994, 5, 43-53.
25. Matecka, D.; Rothman, R. B.; Radesca, L.; de Costa, B. R.; Dersch, C. M.; Partilla, J. S.; Pert, A.; Glowa, J. R.; Wojnicki, F. H. E.; Rice, K. C. Development of Novel, Potent, and Selective Dopamine Reuptake Inhibitors through Alteration of the Pip-erazine Ring of 1-[2-(Diphenylmethoxy)ethyl]-and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl-4-(3-phenylpropyl)piperazine(GBR 12935 and GBR 12909). J. Med. Chem. 1996, 39, 4704-4716.
26. Dutta, A. K.; Meltzer, P. C.; Madras, B. K. Positional importance of the nitrogen atom in novel piperidine analogs of GBR 12909: Affinity and selectivity for the dopamine transporter. Med. Chem. Res. 1993, 3, 209-222.
27. Madras, B. K.; Reith, M. E.; Meltzer, P. C.; Dutta, A. K. 0-526, a piperidine analog of GBR 12909, retains high affinity for the dopamine transporter in monkey caudate-putamen. Eur. J. Pharmacol. 1894, 267, 167-173.
28. Rothman, R. B.; Lewis, B.; Dersch, C.; Xu, H., Radesca, L.; de Costa, B. R.; Rice, K. C.; Kilburn, R. B.; Akunne, H. C.; Pert, A. Identification of a GBR 12935 homolog, LR 1111, which is over 4,000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters, Synapse 1993, 14, 34-39.
29. Matecka, D.; Lewis, D.; Rothman, R. B.; Dersch, C. M.; Radesca, L.; de Costa, B. R.; Dersch, C. M.; Wojnicki, F. H. E.; Glowa, J. R.; DeVries, A C.; Pert, A.; Rice, K. C.; Rice, K. C. Heteroaromatic Analogs of 1-[2-(Diphenylmethoxy)ethyl]-and 1-[2-[Bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as High Affinity Dopamine Reuptake Inhibitors. J. Med. Chem. 1997, 40, 705-716.
30. Rothman, R. B. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug development. Life Sci. 1990, 46, 1990, 17-21.
31. 3H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in the central nervous system. Eur. J. Pharmacol. 1986, 126, 211-222.
32. Aspinal, S.R. Asynthesis of Monoketopiperazine. J. Am. Chem. Soc. 1940, 62, 1202-1204.
33. Hanson, R. N.; Choi, S-W.; Elmaleh, D. R.; Fischman, A J, Synthesis and Evaluation of Novel-N-[2-(Bis-Aryl-Methoxy)-Ethyl-N′-Aralkyl-α,ω- Alkanediamines as Potent and Selective Dopamine Reuptake Inhibitors: Seco Analogs of GBR 12935 and GBR 12909. Bioorg. Med. Chem. Lett. 1991, 7, 2559-2564.
34. Dutta, A. K.; Coffey, L. L.; Reith, M. E. A. High Selective, Novel Analogs of 4-[2-(Diphenylmethoxy)ethyl]-1-benzylpiperidine for the Dopamine Transporter: Effect of Different Aromatic Substitutions on Their Affinity and Selectivity. J. Med. Chem. 1997, 40, 35-43.
35. Dutta, A. K; Xu, C.; Reith, M. E. Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter. J. Med. Chem. 1998, 41, 3293-3297.
36. Eshleman, A. J.; Carmolli, M.; Cumbay, M.; Martens, C. R.; Neve, K. A.; Janowsky, A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol Exp. Ther. 1999, 289, 877-885.
37. 3H]Substrate-and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux. Synapse 1998, 30, 97-106.